

February 9, 2021

To: Ontario Securities Commission, as Principal Regulator

And to: British Columbia Securities Commission  
Alberta Securities Commission  
Financial and Consumer Affairs Authority of Saskatchewan  
Manitoba Securities Commission  
New Brunswick Financial and Consumer Services Commission  
Nova Scotia Securities Commission  
Prince Edward Island Securities Office  
Securities NL, Government of Newfoundland and Labrador

Dear Sirs/Mesdames:

**RE: Short Form Prospectus of Revive Therapeutics Ltd. dated February 9, 2021**

In connection with the final short form prospectus of Revive Therapeutics Ltd. dated February 9, 2021 (the "**Prospectus**"), we consent to the references to our name, Dentons Canada LLP, on page (iii) of the Prospectus and under the heading "*Legal Matters*", and to the use of our name and legal opinions under the headings "*Eligibility for Investment*" and "*Certain Canadian Federal Income Tax Considerations*" in the Prospectus.

We confirm that we have read the Prospectus and have no reason to believe that there are any misrepresentations in the information contained therein that is derived from our legal opinions or that is within our knowledge as a result of the services we performed in connection with such opinions.

Yours truly,

"Dentons Canada LLP"